Amplia Therapeutics Ltd (OP:INNMF)

Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live from investors.

Life Sciences Virtual Investor Forum Agenda Announced

September 14, 2026

Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer

Performance

52-Week Range 81.4% below 52-week high

0.0501

0.0552W Low 0.2752W High

1 Week 44.6% below 1-week high

0.051W Low 0.091W High

Amplia Therapeutics Ltd (INNMF) traded between $0.05 and $0.27 over the past 52 weeks and last traded at $0.05, 81.4% below its 52-week high. Over the past week it ranged between $0.05 and $0.09.

Past 12 Months

-28.4%

-38.7%

-12.1%

-45.2%

-53.6%

-54.5%

1W -$0.02

1M -$0.03

3M -$0.01

6M -$0.04

YTD -$0.06

1Y -$0.06

INNMF was -54.5% over the past year, -45.2% over six months, -53.6% year to date, -28.4% in the last week.

12 Months vs Market

INNMF

-54.5%

DIA

+12.1%

SPY

+17.3%

QQQ

+23.5%

IWM

+13.2%

Over the past 12 months INNMF returned -54.5% versus DIA (Dow) +12.1%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +23.5% and IWM (Russell 2000) +13.2%.

Volume & Liquidity

46.8K

30.8K

25.5K

YTD

22.1K

21.5K

INNMF's 3-month average daily volume is 25.5K.

More News

August 04, 2026

Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online

July 31, 2026

Amplia Announces Publication of New FAK Inhibitor Patent Application

July 09, 2026

Amplia Announces Appointment of Brett Carter to Board

July 07, 2026

Amplia Announces Changes to Board’s Leadership Roles

July 06, 2026

Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer

June 22, 2026

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

May 19, 2026

Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study

May 08, 2026

Accent Trial Mature Data Presented at International Conference

April 22, 2026

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

March 23, 2026

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

March 13, 2026

Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th

March 11, 2026

Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

March 10, 2026

Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models

March 09, 2026

Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial

February 11, 2026

Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025

January 30, 2026

NARMAFOTINIB Large-Scale Manufactre Complete

January 22, 2026

ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM

January 12, 2026

Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium

December 23, 2025

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

December 19, 2025

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

December 12, 2025

Life Sciences Virtual Investor Forum Agenda Announced for December 11th

December 09, 2025

Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th

December 08, 2025

From Virtual Investor Conferences; Amplia Therapeutics